| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9549a3ecb94cb7ab16cd0a6a546f3ea9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2010-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7d70a5ae733c6f9f99671b9c3870046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17b014f2e724e0b7a50f77bb5ad582af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2630fec119a97fc284f8b3fb04855e2b |
| publicationDate |
2010-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010331812-A1 |
| titleOfInvention |
Pharmaceutical Formulations for Iontophoretic Delivery of an Immunomodulator |
| abstract |
The present invention describes pharmaceutical formulations and methods suitable for iontophoretic delivery of the formulations to a subject. The formulations comprise an immunomodulator, such as imiquimod, and optionally include various agents and excipients. The formulations can be used as a treatment for skin diseases and conditions such as actinic keratosis, basal cell carcinoma and genital warts. The short term iontophoretic delivery of the formulations results in the creation of a depot effect in the skin of the subject, allowing for a sustained delivery. The shortened delivery time minimizes local side effects at the application site. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10934550-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018360966-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10479992-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018263925-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11667915-B2 |
| priorityDate |
2009-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |